AI assistant
ABIONYX Pharma — Capital/Financing Update 2019
Jan 11, 2019
1062_rns_2019-01-11_56d79d8a-2c18-40d1-ab5a-3b303aeeb8da.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
Half-year report on liquidity agreement with Gilbert Dupont
Under the liquidity contract signed between Cerenis Therapeutics and Gilbert Dupont, the following assets were booked to the liquidity account at 31st December 2018:
- Number of shares: 85,203
- Cash balance in the liquidity account: 99,463.14 €
As a reminder, in the last half-year report, at 29th June 2018, the liquidity account stood as follows:
- Number of shares: 85,656
- Cash balance in the liquidity account: 90,256.69 €
About Cerenis Therapeutics
Founded in 2005, Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of HDL-based innovative therapies. CERENIS' expertise has translated into a rich portfolio of programs for the treatment of cardiovascular disease and associated metabolic diseases such as NAFLD and NASH as well as a HDL targeted drug delivery platform in oncology, more specifically in immuno-oncology and chemotherapy. CERENIS is well positioned to become one of the leaders in the HDL therapeutic market, with a broad portfolio of programs in development and several products in clinical phases.
Contacts: Cerenis [email protected] Tel: +33 (0)5 62 24 09 49
NewCap Investors relations Emmanuel Huynh / Louis-Victor Delouvrier [email protected] Tel: +33 (0)1 44 71 98 53